51 related articles for article (PubMed ID: 32336065)
1. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi.
Ma Q; Ma D; Lin M; Gong Y; Han X; Chen Y; Tang Z; Liu M
Biomed Res Int; 2021; 2021():9939065. PubMed ID: 34136575
[TBL] [Abstract][Full Text] [Related]
3. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N
Front Oncol; 2023; 13():1275575. PubMed ID: 38023198
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.
Gao JW; Rizzo S; Ma LH; Qiu XY; Warth A; Seki N; Hasegawa M; Zou JW; Li Q; Femia M; Lv TF; Song Y;
Transl Lung Cancer Res; 2017 Feb; 6(1):68-75. PubMed ID: 28331826
[TBL] [Abstract][Full Text] [Related]
5. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Chu QS
Ther Adv Med Oncol; 2020; 12():1758835919895756. PubMed ID: 32047535
[TBL] [Abstract][Full Text] [Related]
6. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Chalela R; Curull V; Enríquez C; Pijuan L; Bellosillo B; Gea J
J Thorac Dis; 2017 Jul; 9(7):2142-2158. PubMed ID: 28840016
[TBL] [Abstract][Full Text] [Related]
7. Analysis of clinical characteristics and detection of pathogens in patients with pulmonary tuberculosis complicated with fungal infection.
Chen S; Ye J; Wang Y; Tang X; Xie W
Minerva Med; 2023 Oct; 114(5):754-756. PubMed ID: 34672176
[No Abstract] [Full Text] [Related]
8. [
Gu J; Ren Y; Chen X; Jiang Y; Zhou W; Wang L; Han Y; Wang Q; Wu H
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jan; 40(1):49-55. PubMed ID: 32376559
[TBL] [Abstract][Full Text] [Related]
9. Anti-programmed death 1 antibody in the treatment of coexistent
Zhang CC; Chen P
World J Clin Cases; 2022 Apr; 10(12):3801-3807. PubMed ID: 35647142
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor.
Xie Y; Su N; Zhou W; Lei A; Li X; Li W; Huang Z; Cen W; Hu J
Cancer Manag Res; 2021; 13():7517-7526. PubMed ID: 34621133
[TBL] [Abstract][Full Text] [Related]
11. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
12. Molecular Targets Beyond the Big 3.
Reckamp KL
Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
[TBL] [Abstract][Full Text] [Related]
13. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
Deng H; Liu C; Zhang G; Wang X; Liu Y
Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].
Hu Y; Yang X; Nie L; Zhao D; An J; Li B
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):337-342. PubMed ID: 32336065
[TBL] [Abstract][Full Text] [Related]
15. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
16. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
